Sanara MedTech (SMTI)
Market Price (1/22/2026): $22.52 | Market Cap: $194.7 MilSector: Health Care | Industry: Health Care Equipment
Sanara MedTech (SMTI)
Market Price (1/22/2026): $22.52Market Cap: $194.7 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 31% | Weak multi-year price returns2Y Excs Rtn is -85%, 3Y Excs Rtn is -121% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.7% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -31% | Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 52x | |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, Diabetes Management, Show more. | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -23% | |
| Key risksSMTI key risks include [1] its history of unprofitability and a significant debt load, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 31% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -31% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, Diabetes Management, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -85%, 3Y Excs Rtn is -121% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.7% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 52x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -23% |
| Key risksSMTI key risks include [1] its history of unprofitability and a significant debt load, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
1. Discontinuation of Tissue Health Plus (THP) and Associated Impairment Charge:
Sanara MedTech announced on November 11-12, 2025, its strategic decision to discontinue the Tissue Health Plus (THP) segment, classifying it as discontinued operations. This realignment aimed to reallocate resources to the core surgical business. The Q3 2025 financial results, reported on November 12, 2025, revealed a significant non-cash impairment charge of $26.5 million related to THP, contributing to a substantial net loss of $31.2 million from discontinued operations for the quarter. This move reflected past strategic missteps by management in developing THP, leading to a loss of investor trust.
2. Weak Q4 2025 Revenue Guidance:
Following the Q3 2025 earnings report, Sanara MedTech issued Q4 2025 revenue guidance that projected a significant deceleration in growth. The company anticipated high single-digit to low-teens year-over-year revenue growth for Q4 2025, a stark contrast to the robust 49% growth experienced in Q4 2024, which had benefited from increased demand following Hurricane Helene. This weaker outlook led investors to fear a slowdown in the company's growth trajectory and contributed to tax-loss selling.
Show more
Stock Movement Drivers
Fundamental Drivers
The -22.2% change in SMTI stock from 10/31/2025 to 1/21/2026 was primarily driven by a -25.5% change in the company's P/S Multiple.| 10312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 29.30 | 22.79 | -22.2% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 97 | 102 | 4.8% |
| P/S Multiple | 2.6 | 1.9 | -25.5% |
| Shares Outstanding (Mil) | 9 | 9 | -0.4% |
| Cumulative Contribution | -22.2% |
Market Drivers
10/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| SMTI | -22.2% | |
| Market (SPY) | 0.5% | 22.1% |
| Sector (XLV) | 9.7% | -6.4% |
Fundamental Drivers
The -5.7% change in SMTI stock from 7/31/2025 to 1/21/2026 was primarily driven by a -14.5% change in the company's P/S Multiple.| 7312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 24.17 | 22.79 | -5.7% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 92 | 102 | 11.3% |
| P/S Multiple | 2.3 | 1.9 | -14.5% |
| Shares Outstanding (Mil) | 9 | 9 | -0.9% |
| Cumulative Contribution | -5.7% |
Market Drivers
7/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| SMTI | -5.7% | |
| Market (SPY) | 8.7% | 28.3% |
| Sector (XLV) | 21.9% | 11.1% |
Fundamental Drivers
The -37.3% change in SMTI stock from 1/31/2025 to 1/21/2026 was primarily driven by a -51.2% change in the company's P/S Multiple.| 1312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 36.33 | 22.79 | -37.3% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 78 | 102 | 30.6% |
| P/S Multiple | 4.0 | 1.9 | -51.2% |
| Shares Outstanding (Mil) | 9 | 9 | -1.5% |
| Cumulative Contribution | -37.3% |
Market Drivers
1/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| SMTI | -37.3% | |
| Market (SPY) | 14.9% | 38.9% |
| Sector (XLV) | 9.2% | 32.2% |
Fundamental Drivers
The -47.7% change in SMTI stock from 1/31/2023 to 1/21/2026 was primarily driven by a -79.4% change in the company's P/S Multiple.| 1312023 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 43.55 | 22.79 | -47.7% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 38 | 102 | 171.3% |
| P/S Multiple | 9.4 | 1.9 | -79.4% |
| Shares Outstanding (Mil) | 8 | 9 | -6.7% |
| Cumulative Contribution | -47.9% |
Market Drivers
1/31/2023 to 1/21/2026| Return | Correlation | |
|---|---|---|
| SMTI | -47.7% | |
| Market (SPY) | 74.9% | 39.0% |
| Sector (XLV) | 24.2% | 30.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SMTI Return | -41% | 54% | -10% | -19% | -30% | -7% | -56% |
| Peers Return | -4% | -46% | 74% | 12% | -9% | -9% | -17% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| SMTI Win Rate | 50% | 50% | 42% | 42% | 33% | 0% | |
| Peers Win Rate | 54% | 38% | 57% | 47% | 38% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 0% | |
Max Drawdowns [4] | |||||||
| SMTI Max Drawdown | -54% | -38% | -42% | -35% | -43% | -7% | |
| Peers Max Drawdown | -19% | -57% | -27% | -34% | -31% | -11% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: IART, MDXG, ORGO, BVS, SYK.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/21/2026 (YTD)
How Low Can It Go
| Event | SMTI | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -63.3% | -25.4% |
| % Gain to Breakeven | 172.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -60.5% | -33.9% |
| % Gain to Breakeven | 153.1% | 51.3% |
| Time to Breakeven | 215 days | 148 days |
| 2008 Global Financial Crisis | ||
| % Loss | -58.6% | -56.8% |
| % Gain to Breakeven | 141.7% | 131.3% |
| Time to Breakeven | 3,508 days | 1,480 days |
Compare to IART, MDXG, ORGO, BVS, SYK
In The Past
Sanara MedTech's stock fell -63.3% during the 2022 Inflation Shock from a high on 1/1/2021. A -63.3% loss requires a 172.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-2 brief analogies for Sanara MedTech (SMTI):
- Like Medtronic for advanced wound care and surgical biologics.
- Like Smith & Nephew for next-generation wound care solutions.
AI Analysis | Feedback
- PuraPly® AM: An antimicrobial wound matrix designed to manage and support healing in a variety of complex wounds.
- Surgical Biologics: A portfolio of advanced biological products, such as ALLOSHIELD™ and BIOCORIUM®, used to support tissue repair and regeneration in surgical applications.
- Advanced Wound Care Dressings: A diverse range of topical wound care products, including HYDRALUXE™ and SilverSeal®, designed to protect wounds and facilitate healing.
- Negative Pressure Wound Therapy (NPWT) Systems: Medical devices that apply controlled negative pressure to wounds to promote faster healing by removing exudate and reducing edema.
- Advanced Wound Care Outcomes Tracking and Analysis Platform: A digital platform that provides tools for monitoring, tracking, and analyzing wound care treatment progress and patient outcomes.
AI Analysis | Feedback
Sanara MedTech (SMTI) sells primarily to other companies and institutions, operating on a business-to-business (B2B) model.
According to its most recent annual report (10-K), Sanara MedTech does not have any single customer that accounted for 10% or more of its total revenue. Therefore, no individual major customer companies are disclosed by name with their symbols.
However, Sanara MedTech's primary customers are various healthcare providers and facilities that utilize its surgical, wound, and skin care products. These customer categories include:
- Hospitals: Acute care facilities where surgical procedures are performed and complex wounds are managed.
- Wound Care Clinics: Specialized outpatient centers focused on the treatment and management of chronic and non-healing wounds.
- Physicians' Offices and Long-Term Care Facilities: Including various private practices, ambulatory surgical centers, and extended care settings where their products are used for patient treatment.
AI Analysis | Feedback
AI Analysis | Feedback
Seth Yon, President and Chief Executive Officer
Seth Yon was appointed President and Chief Executive Officer of Sanara MedTech effective September 15, 2025. He joined Sanara MedTech in March 2018 as Director of Sales, Wound Care, and has held several senior leadership positions, including National Sales Director, Vice President of Commercial, President of Commercial, and President and Chief Commercial Officer. Before joining Sanara, he served as Vice President of Sales and Marketing for Iroquois Industrial Group from 2015 to 2018. Mr. Yon also founded GreenerGrads, which he led from 2011 to 2014, and began his career at Jostens, Inc.
Elizabeth Taylor, Chief Financial Officer
Elizabeth Taylor was appointed Chief Financial Officer of Sanara MedTech effective January 15, 2025. Prior to Sanara, she served as CFO of Imbed Biosciences, a privately held medical device company, from 2023 to 2025, and was a member of its board of directors from 2018 to 2023. Her experience includes roles as Chief Operating Officer of multiple hedge funds and as a member of the investment team at a private equity firm. Ms. Taylor founded Burnett Taylor Consulting, LLC, which provided financial advisory services for family offices and high-net-worth clients. She also held leadership positions at Citadel Investment Group, Tala Investments, LP, and Thomas H. Lee Partners.
Ron Nixon, Executive Chairman
Ron Nixon serves as the Executive Chairman of Sanara MedTech. He is the Founder and Managing Partner of The Catalyst Group, Inc., a private investment firm established in 1990, and has been involved in over 200 transactions. Mr. Nixon served as CEO of Sanara MedTech from May 2024 until September 2025, and as Executive Chairman since May 2019. He has served on the board of directors for several privately held companies and was a director for LHC Group, Inc. The Catalyst Group was an early investor in LHC Group. He previously served as CEO of Tissue Health Plus LLC.
Jake Waldrop, Chief Operating Officer
Jake Waldrop joined Sanara MedTech as Chief Operating Officer in April 2024. He brings two decades of experience leading cross-functional teams in the technology and medical device industries. Previously, Mr. Waldrop was Chief Financial Officer for Trilliant Surgical. Following Trilliant Surgical's acquisition by Enovis in early 2021, he became Vice President of Finance and Integrations for Enovis' newly formed Foot and Ankle division.
Tyler Palmer, Chief Corporate Development and Strategy Officer
Tyler Palmer was appointed Chief Corporate Development and Strategy Officer in April 2024. He has extensive experience in the healthcare sector, particularly in leading strategic growth and corporate development initiatives. Prior to Sanara, Mr. Palmer served as Senior Vice President of Corporate Development, Strategy, and Product at AQuity Solutions. He has also held various leadership roles in corporate development, marketing, and business unit leadership within the Orthopedic, Surgical, and Wound Care sectors at companies such as Zimmer, BSN medical, and Essity.
AI Analysis | Feedback
The key risks to Sanara MedTech's business include its history of unprofitability and debt, execution challenges within its surgical segment, and inherent regulatory and product-related risks.
- Persistent Unprofitability and Debt: Sanara MedTech has a history of net losses, largely attributed to its now-discontinued Tissue Health Plus (THP) segment. The company also carries a notable amount of debt with a high interest rate, and its balance sheet has been described as weak. While the discontinuation of the THP segment is expected to improve its financial position, the company faces the immediate challenge of achieving consistent overall profitability and effectively managing its debt load.
- Execution Risk in the Surgical Segment: With the THP segment wound down, Sanara MedTech's financial success is now primarily dependent on the performance and growth of its surgical product segment. Key risks involve the company's ability to continue penetrating existing and new hospitals with its current product lines (such as CellerateRX Surgical and BIASURGE) and successfully commercialize new products in its pipeline. Any slowdown in the surgical segment's growth could significantly impact revenue and profitability.
- Regulatory and Product-Related Risks: As a medical technology company, Sanara MedTech operates in a highly regulated environment. The business is susceptible to risks associated with product defects, failures, or quality issues, which could lead to product recalls, adverse regulatory actions, product liability lawsuits, and negative public perception. Furthermore, delays in obtaining necessary regulatory clearances or approvals for new products could hinder their commercialization, and issues related to "off-label" promotion carry the potential for substantial penalties.
AI Analysis | Feedback
nullAI Analysis | Feedback
Sanara MedTech (SMTI) operates in several addressable markets within the medical technology sector. The company's Tissue Health Plus (THP) platform targets a non-surgical wound care market estimated to be a $69 billion opportunity in the U.S.. Additionally, Sanara MedTech aims to capture market share within a surgical solutions market, which represents a $10 billion+ opportunity in the United States.
AI Analysis | Feedback
Sanara MedTech (SMTI) is poised for future revenue growth over the next 2-3 years, driven by several key factors:
- Continued Growth in Sanara Surgical Segment: The Sanara Surgical segment is consistently highlighted as the primary engine for net revenue growth. This includes strong sales of its existing soft tissue repair products, such as CellerateRX Surgical and BIASURGE, and contributions from its bone fusion product portfolio. The company emphasizes effective execution by its commercial team and a significant "greenfield opportunity" within this segment.
- Expansion of Customer Base and Product Adoption: A significant driver for future revenue is the increasing number of healthcare facilities utilizing SMTI's products and the expansion of its distributor network. In the second quarter of 2025, the number of distributors increased by 33% year-over-year to 400, and the number of healthcare facilities using SMTI's products grew by 27% year-over-year to 1,400. This indicates sustained revenue growth as product adoption continues to rise within its customer base.
- Commercialization of the Tissue Health Plus (THP) Segment: While currently in an investment and pilot phase, with management exploring strategic alternatives and capping further investments, the eventual commercialization of the Tissue Health Plus (THP) segment and its value-based wound care strategy is anticipated to become a future revenue driver. The company is actively investing in and preparing for the launch of a pilot program for this segment.
- Launch of New Products and Product Portfolio Expansion: Sanara MedTech's strategic initiatives include expanding its product portfolio. This is evidenced by a strategic license agreement with Rochal to develop antimicrobial products, which diversifies its offerings. The company also received an FDA Breakthrough Device Designation for a new product in Q4 2024, highlighting its commitment to developing innovative solutions.
- Strategic Alliances and Acquisitions: Strategic partnerships and acquisitions are expected to contribute to revenue growth. Notable examples include the formation of a strategic alliance with BioMimetic Innovations, mentioned in the Q4 2024 earnings report, and the acquisition of CarePICS, THP's technology partner, in Q2 2025, which aims to strengthen the company's offerings.
AI Analysis | Feedback
Share Issuance
- In February 2021, Sanara MedTech closed a public offering of 1,265,000 shares of common stock at $25.00 per share, generating gross proceeds of $31.6 million.
- The number of shares outstanding increased by 1.87% in one year, reaching 8.90 million shares.
Outbound Investments
- On January 21, 2025, Sanara announced an exclusive license and distribution agreement with, and a minority investment in, Biomimetic Innovations Ltd (BMI), securing exclusive U.S. marketing, sales, and distribution rights for BMI's OsStic® product.
- In August 2023, Sanara acquired the underlying intellectual property and manufacturing/sales rights for CellerateRX Surgical and HYCOL products from Applied Nutritionals.
- During 2022, the company made two acquisitions: Precision Healing Inc. in April (for a diagnostic imager and lateral flow assay) and Scendia Biologics, LLC in July (to expand surgical offerings with regenerative and orthobiologic technologies).
Capital Expenditures
- Capital expenditures in the last 12 months amounted to approximately $3.57 million.
- Sanara plans to invest an estimated $5.5 million to $10 million through mid-2025 to build out its Tissue Health Plus strategy and infrastructure.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Sanara MedTech Earnings Notes | 12/16/2025 | |
| Can Sanara MedTech Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Sanara MedTech
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.09 |
| Mkt Cap | 0.7 |
| Rev LTM | 514 |
| Op Inc LTM | 40 |
| FCF LTM | 26 |
| FCF 3Y Avg | 34 |
| CFO LTM | 62 |
| CFO 3Y Avg | 39 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.0% |
| Rev Chg 3Y Avg | 6.9% |
| Rev Chg Q | 15.9% |
| QoQ Delta Rev Chg LTM | 3.6% |
| Op Mgn LTM | 5.2% |
| Op Mgn 3Y Avg | 3.7% |
| QoQ Delta Op Mgn LTM | 1.5% |
| CFO/Rev LTM | 7.7% |
| CFO/Rev 3Y Avg | 7.1% |
| FCF/Rev LTM | 4.3% |
| FCF/Rev 3Y Avg | 3.8% |
Price Behavior
| Market Price | $22.79 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -40.2% | |
| 50 Days | 200 Days | |
| DMA Price | $23.04 | $28.30 |
| DMA Trend | down | down |
| Distance from DMA | -1.1% | -19.5% |
| 3M | 1YR | |
| Volatility | 73.5% | 60.1% |
| Downside Capture | 84.62 | 147.02 |
| Upside Capture | -93.01 | 85.92 |
| Correlation (SPY) | 16.8% | 38.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.27 | 0.98 | 1.15 | 1.69 | 1.19 | 1.34 |
| Up Beta | 0.26 | 4.91 | 3.77 | 4.00 | 1.35 | 1.45 |
| Down Beta | -0.72 | 3.02 | 2.44 | 1.72 | 0.96 | 1.11 |
| Up Capture | 200% | -160% | -88% | 40% | 79% | 123% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 11 | 20 | 29 | 55 | 112 | 341 |
| Down Capture | -49% | 1% | 52% | 130% | 123% | 110% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 11 | 21 | 35 | 71 | 136 | 404 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SMTI | |
|---|---|---|---|---|
| SMTI | -28.4% | 60.2% | -0.32 | - |
| Sector ETF (XLV) | 14.5% | 17.4% | 0.62 | 31.1% |
| Equity (SPY) | 15.8% | 19.3% | 0.63 | 39.1% |
| Gold (GLD) | 79.5% | 20.4% | 2.78 | 4.2% |
| Commodities (DBC) | 5.7% | 15.3% | 0.16 | 17.2% |
| Real Estate (VNQ) | 5.8% | 16.7% | 0.17 | 33.3% |
| Bitcoin (BTCUSD) | -14.7% | 39.8% | -0.31 | 27.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SMTI | |
|---|---|---|---|---|
| SMTI | -6.7% | 58.9% | 0.12 | - |
| Sector ETF (XLV) | 7.9% | 14.5% | 0.36 | 25.3% |
| Equity (SPY) | 14.0% | 17.1% | 0.66 | 35.2% |
| Gold (GLD) | 20.8% | 15.7% | 1.07 | 7.2% |
| Commodities (DBC) | 11.4% | 18.7% | 0.49 | 10.4% |
| Real Estate (VNQ) | 5.7% | 18.8% | 0.21 | 28.8% |
| Bitcoin (BTCUSD) | 19.0% | 58.0% | 0.53 | 17.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SMTI | |
|---|---|---|---|---|
| SMTI | 84.1% | 2,484.5% | 0.43 | - |
| Sector ETF (XLV) | 10.6% | 16.6% | 0.53 | 0.5% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 1.6% |
| Gold (GLD) | 15.7% | 14.9% | 0.87 | 0.6% |
| Commodities (DBC) | 8.2% | 17.6% | 0.38 | 0.5% |
| Real Estate (VNQ) | 5.8% | 20.8% | 0.25 | 2.5% |
| Bitcoin (BTCUSD) | 70.3% | 66.7% | 1.09 | 2.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2025 | -24.7% | -25.5% | -7.6% |
| 8/13/2025 | 16.2% | 12.3% | 28.4% |
| 5/14/2025 | -10.8% | -11.6% | -18.3% |
| 1/21/2025 | 10.9% | 10.7% | 3.9% |
| 11/12/2024 | 7.6% | 6.8% | 3.6% |
| 8/12/2024 | 15.1% | 17.6% | 20.4% |
| 5/13/2024 | -6.8% | -2.9% | -1.4% |
| 2/22/2024 | 0.0% | 0.2% | -1.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 13 | 10 |
| # Negative | 7 | 8 | 11 |
| Median Positive | 4.8% | 6.3% | 15.9% |
| Median Negative | -8.4% | -12.0% | -9.2% |
| Max Positive | 19.4% | 17.6% | 58.1% |
| Max Negative | -24.7% | -25.5% | -21.0% |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.